Press Release
Shire reports Q3 2016 results with record revenues and reiterates full year Non
GAAP guidance
Very strong U.S. launch for XIIDRA; marks outstanding entry into ophthalmics
Baxalta integration progressing well with synergy initiatives ahead of plan
November 1, 2016 – Shire plc (Shire) (LSE: SHP, NASDAQ: SHPG) announces unaudited results for the three months
ended September 30, 2016.
Financial Highlights
Product sales
Product sales excluding Baxalta products
Total revenues

Q3 2016(1)$3,315 million$1,769 million$3,452 million

Growth(1)
+110%
+12%
+109%

Non GAAP CER(1)(2)
+111%
+13%
+109%

US GAAP operating loss from continuing operations
Non GAAP operating income(2)($406 million)$1,254 million(189%)
+73%

+71%

(11%)
38%

(38ppc)(5ppc)($387 million)$962 million(185%)+50%($1.29)$3.17(156%)(2%)$526 million$830 million$395 million

(6%)
+41%
(27%)

US GAAP net income margin(3)(4)
Non GAAP EBITDA margin(2)(4)US GAAP net loss
Non GAAP net income(2)US GAAP diluted losses per ADS
Non GAAP diluted earnings per ADS(2)US GAAP net cash provided by operating activities
Non GAAP cash generation(2)Non GAAP free cash flow(2)

(3%)

(1)

Results include Baxalta Inc. (Baxalta) (acquired on June 3, 2016) and Dyax Corp. (Dyax) (acquired on January 22, 2016), unless otherwise noted.
Percentages compare to equivalent 2015 period. (2) The Non GAAP financial measures included within this release are explained on pages 27 –28, and are reconciled to the most directly comparable financial measures prepared in accordance with US GAAP on pages 21 – 23. (3) US GAAP
net income as a percentage of total revenues. (4) Percentage point change (ppc).

Financial highlights• Very strong launch results for XIIDRA; 64,732 scripts written through October 21, with a market share of 16%.
• Product sales growth of 110% in Q3 2016 to $3.3 billion, driven by record legacy Shire product sales and theinclusion of legacy Baxalta franchises.
• Underlying growth in Q3 2016 hematology and immunology businesses largely in line with overall market trends;
pro forma sales growth of legacy Baxalta products impacted by the timing of large orders.
• Q3 2016 year to date growth for legacy Shire product sales was 15% (16% on a Non GAAP CER basis) and legacy
Baxalta was 7% on a pro forma basis (8% on a Non GAAP CER pro forma basis), in line with our expectations.

Baxalta integration• Operating expense synergy initiatives ahead of schedule, including manufacturing footprint optimization review.
• Sharp focus on transitioning legacy Baxalta products onto Shire’s commercial platform and operating execution.
• Issued $12.1 billion aggregate principal debt at a weighted average interest rate of 2.6%; net proceeds used to fully
repay bridge facility for financing Baxalta transaction.

Pipeline progress• Pipeline continuing to deliver with U.S. Food and Drug Administration (FDA) approval of CUVITRU, and European
Commission (EC) Marketing Authorization for ONIVYDE accompanied by Orphan Drug Designation.
• Fully enrolled Phase 3 study for SHP643 in prophylaxis of hereditary angioedema with results expected in the firsthalf of 2017.
• FDA resubmission of SHP465 for the treatment of ADHD on track to be made in Q4 2016.
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX

Flemming Ornskov, M.D., M.P.H., Shire Chief Executive Officer, commented:“During the third quarter, we made rapid progress integrating our new company while delivering record quarterly
product sales growth and remaining on track to meet our full year Non GAAP guidance. The launch of XIIDRA is off
to a very strong start, and we are using this momentum to build a leadership position in pharmaceutical
ophthalmics. Commercial execution remains a top priority across the business. Also, our robust pipeline iscontinuing to advance, and we look forward to highlighting key programs during our upcoming Investor Day. Thechanges we are applying to the legacy Baxalta business are similar to the One Shire initiative we undertook in
2013-2014, which set off a period of strong growth and profitability. I am highly confident about Shire’s future growthprospects.”

2

FINANCIAL SUMMARY - THIRD QUARTER 2016
Revenues• Total product sales increased 110% versus Q3 2015 (up 111% on a Non GAAP CER basis) to $3,315 million(Q3 2015: $1,577 million), primarily due to the inclusion of $1,546 million of legacy Baxalta sales.
•

Excluding Baxalta, product sales increased 12% (13% on a Non GAAP CER basis) with all legacy Shire
franchises exhibiting growth in Q3 2016, with Neuroscience up 15%, Genetic Diseases up 5% and Internal
Medicine up 15% compared with Q3 2015. Following the launch of XIIDRA in August 2016, our Ophthalmology
franchise contributed sales of $14 million.

•

Royalties and other revenues increased 75% to $137 million, as Q3 2016 benefited from additional revenue
acquired with Baxalta, primarily related to contract manufacturing activities.

Operating results• Research and Development (R&D) expenses increased by 112% compared with Q3 2015, primarily due to theinclusion of Baxalta and Dyax operating costs, and costs related to licensing SHP647. Non GAAP R&D
increased by 68% in Q3 2016 primarily due to the inclusion of Baxalta and Dyax operating costs.
•

Selling, General and Administrative (SG&A) expenses increased by 98% compared with Q3 2015, primarily due
to the inclusion of Baxalta operating costs and XIIDRA launch costs. Non GAAP SG&A increased by 103% in
Q3 2016.

•

On a US GAAP basis, the operating loss was $406 million in Q3 2016 (Q3 2015: operating income of $456
million). The operating loss in Q3 2016 was primarily due to the impact of acquisition accounting, including
higher amortization of inventory fair value step up and amortization of acquired intangible assets, combinedwith higher integration and acquisition costs. Non GAAP operating income increased 73% to $1,254 million (Q32015: $725 million), primarily due to the inclusion of a full quarter of Baxalta operating income and higher
revenue from legacy Shire products.

•

Non GAAP EBITDA margin (excluding royalties and other revenue, and cost of sales related to contract
manufacturing revenues) was 38% (Q3 2015: 43%). The decrease was primarily due to the impact of a fullquarter of lower margin product franchises acquired with Baxalta and XIIDRA launch costs.

Earnings per share (EPS)• On a US GAAP basis, diluted losses per American Depositary Shares (ADS) were $1.29 (Q3 2015: earnings
per ADS of $2.29). The Q3 2016 loss was primarily due to lower US GAAP operating income resulting from theimpact of acquisition accounting, including higher amortization of inventory fair value step up and amortizationof acquired intangible assets, combined with higher integration and acquisition costs, all primarily related to the
Baxalta transaction.
•

Non GAAP diluted earnings per ADS decreased 2% to $3.17 (Q3 2015: $3.24), as higher Non GAAP operating
income was more than offset by the additional shares issued as consideration for the Baxalta transaction.

Cash flows• On a US GAAP basis, net cash provided by operating activities decreased 6% to $526 million (Q3 2015: $561
million), primarily due to a payment associated with the termination of a biosimilar collaboration acquired with
Baxalta, an increase in costs related to the Baxalta integration and higher tax and interest payments, partially
offset by strong cash receipts from higher sales.
•

Non GAAP cash generation increased 41% to $830 million (Q3 2015: $588 million), primarily due to strong cash
receipts from higher sales, partially offset by a payment associated with the termination of a biosimilar
collaboration acquired with Baxalta and an increase in costs related to the Baxalta integration.

•

Non GAAP free cash flow decreased 27% to $395 million (Q3 2015: $539 million), primarily due to the decreasein net cash provided by operating activities described above combined with an increase in capital expendituresof $199 million in support of manufacturing operations.

Debt• Non GAAP net debt at September 30, 2016 was $23,346 million (December 31, 2015: $1,459 million)
representing aggregate long and short term borrowings of $23,726 million, primarily used to fund theacquisitions of Baxalta and Dyax and other debt primarily related to capital leases of $349 million, partially
offset by cash and cash equivalents of $729 million.

3

OUTLOOK
After our first full quarter following the acquisition of Baxalta, we are reiterating our non-GAAP guidance from Q2 2016
and updating our US GAAP guidance.
The full year 2016 guidance includes the legacy Baxalta business as of June 3, 2016. The guidance includes expected
operating cost synergy savings for 2016 based on our target of at least $700 million in year three post close.
The Non GAAP diluted earnings per ADS forecast assumes a weighted average number of 778 million fully diluted
ordinary shares outstanding for 2016 following the equity issuance for the Baxalta transaction.
Our US GAAP diluted earnings per ADS outlook has been updated to reflect an increase in integration costs related
to the Baxalta transaction, costs related to licensing SHP647 and reorganization costs associated with the planned
closure of a facility in our Los Angeles manufacturing site.
Full Year 2016
Total product sales
Royalties & other revenues
Gross margin
Combined R&D and SG&A
Net interest/other
Effective tax rate(2)Diluted earnings per ADS(3)US GAAP Outlook$10.8 - $11 billion$490 - $530 million
58% - 60%
$4.3 - $4.7 billion$500 - $550 million
92% - 136%($1.10) - ($0.70)

Non GAAP Outlook(1)$10.8 - $11 billion$490 - $530 million
77% - 79%
$4.1 - $4.4 billion$400 - $450 million
16% - 18%
$12.70 - $13.10(1)

For a list of items excluded from Non GAAP Outlook, refer to pages 27-28 of this release.
For 2016, we expect our effective tax benefit rate on GAAP pre-tax losses from operations to be in the range of 92% - 136%. The GAAP effective
tax rate for 2016 is highly sensitive to the relative quantum of profit or loss before tax, leading to the wide range of the expected GAAP effective
tax rate.
(3)
See page 23 for a reconciliation between US GAAP diluted earnings per ADS and Non GAAP diluted earnings per ADS.
(2)

4

RECENT DEVELOPMENTS
Financing
Senior notes issuance•

On September 23, 2016, Shire issued $12.1 billion aggregate principal amount of senior notes, consisting offour series:◦ $3.3 billion 1.900% Senior Notes due 2019;◦ $3.3 billion 2.400% Senior Notes due 2021;◦ $2.5 billion 2.875% Senior Notes due 2023; and◦ $3.0 billion 3.200% Senior Notes due 2026•

Shire used the net proceeds to fully repay amounts outstanding under its January 2016 bridge facility
agreement, which were used to finance its acquisition of Baxalta and for general corporate purposes.

Business Development
Pacritinib for the treatment of myelofibrosis•

On October 21, 2016, Shire and CTI BioPharma Corp. (CTI) entered into an Asset Return and Termination
Agreement pursuant to which the license arrangement between the parties was terminated in its entirety andall rights relating to pacritnib were returned to CTI.

Biosimilars (etanercept and adalimumab)•

Shire has terminated its relationship with SFJ Pharmaceuticals, Inc. and its biosimilar collaboration with
Coherus BioSciences, Inc. Additionally, Shire has delivered notice of exercise of its right to terminate its
biosimilar collaboration with Momenta Pharmaceuticals, Inc. and such termination will be effective upon
expiration of the applicable termination notice period. These collaborations were acquired through the Baxalta
acquisition.

Products
ONIVYDE for the treatment of pancreatic cancer•

On October 18, 2016, Shire announced that the EC granted Marketing Authorization to ONIVYDE (pegylated
liposomal irinotecan hydrochloride trihydrate), for the treatment of metastatic adenocarcinoma of the pancreas,in combination with 5-fluorouracil and leucovorin, in adult patients who have progressed following gemcitabinebased therapy. This approval is accompanied by an Orphan Drug Designation for ONIVYDE.

VYVANSE for the treatment of moderate to severe binge eating disorder (BED)•

On September 30, 2016, Health Canada approved VYVANSE for the treatment of BED in adults. The launchis on track for Q4 2016.

•

On October 17, 2016, Shire announced the approval of a supplemental NDA by the FDA. The VYVANSE label
will include the new longer-term maintenance of efficacy data in adults with moderate to severe BED.

LIALDA for the treatment of ulcerative colitis•

On September 28, 2016, Mochida Pharmaceutical Co., Ltd announced that the Japanese Ministry of Health,Labour and Welfare approved LIALDA 1200mg for the treatment of adults with ulcerative colitis.

CUVITRU for the treatment of primary immunodeficiency disorders•

On September 14, 2016, Shire announced that the FDA granted approval for CUVITRU [Immune Globulin
Subcutaneous (Human), 20% Solution] in adult and pediatric patients two years of age and older.

5

XIIDRA for the treatment of dry eye disease•

On August 29, 2016, Shire announced that XIIDRA (lifitegrast ophthalmic solution) 5%, a twice-daily prescription
eye drop indicated for the treatment of both the signs and symptoms of dry eye disease, became available byprescription in the U.S. The FDA approved XIIDRA on July 11, 2016.

•

On October 28, 2016, a New Drug Submission (NDS) was filed with Health Canada for lifitegrast ophthalmic
solution 5%. This submission marks the first step towards Shire's international expansion activities for lifitegrast.

VONVENDI for the treatment of adults affected by von Willebrand disease (VWD)•

On August 9, 2016, Shire announced the U.S. launch of VONVENDI [von Willebrand factor (Recombinant)],
the only recombinant treatment for adults living with VWD.

Pipeline
SHP610 for the treatment of Sanfilippo Syndrome type A (MPS-IIIA) (Sanfilippo A)•

The Phase 2b study of SHP610 in pediatric patients with early stage Sanfilippo A did not meet its primary
endpoint of slowing the cognitive decline in patients. Shire intends to terminate all clinical trials of SHP610
and plans to publish the results of the SHP610 program for the benefit of the Sanfilippo community.

SHP643 for the treatment of Hereditary Angioedema•

The pivotal Phase 3 study completed enrollment in September 2016 with 125 patients enrolled. The topline
data readout is expected in Q2 2017.

SHP609 for the treatment of Hunter Syndrome•

The pivotal Phase 3 study completed enrollment in September 2016 with 49 patients enrolled. The topline
data readout is expected in Q4 2017.

Legal Proceedings
Patent Trial and Appeal Board issues decision regarding GATTEX patent•

On October 21, 2016, the U.S. Patent & Trademark Office’s Patent Trial and Appeal Board (PATB) issued adecision holding certain claims of U.S. Patent 7,056,886 (the ‘886 patent) invalid, following an inter partes
review (IPR) challenge by the Coalition for Affordable Drugs II L.L.C. (CFAD). Shire is currently reviewing thedecision and will decide whether to appeal. The PTAB had earlier declined to review certain claims of the ‘886
patent that had been challenged by CFAD. Claims of the FDA Orange Book-listed ‘886 patent that were notreviewed in the IPR proceedings remain in force. In addition, GATTEX has orphan drug exclusivity until
December 2019, and is also protected by Orange Book-listed patents expiring in 2020 and 2025.

Patent Trial and Appeal Board upholds the validity of LIALDA patent•

On October 5, 2016, Shire announced that the PTAB issued a decision upholding the validity of U.S. Patent
No. 6,773,720, related to LIALDA.

District Court issues ruling in Hatch Waxman Case regarding LIALDA•

On September 16, 2016, the U.S. District Court for the District of Delaware ruled that Cadilla Healthcare Ltd./
Zydus Pharmaceuticals (USA) Inc.’s (Zydus) proposed generic version of LIALDA does not infringe U.S Patent
No. 6,773,720 (the ‘720 patent). Shire has appealed this ruling to the Court of Appeals of the Federal
Circuit. Shire believes that the proposed Zydus product infringes the ‘720 patent and will continue to vigorously
defend its intellectual property rights.

6

ADDITIONAL INFORMATION
The following additional information is included in this press release:
Page
Overview of Third Quarter 2016 Financial Results

8

Financial Information

13

Non GAAP Reconciliations

21

Notes to Editors

24

Forward-Looking Statements

25

Non GAAP Measures

27

Trademarks

28

For further information please contact:
Investor Relations
Sarah Elton-Farr
Ian Karp
Robert Coates

seltonfarr@shire.com
ikarp@shire.com
rcoates@shire.com+44 1256 894157+1 781 482 9018
+44 1256 894874

Media
Gwen Fisher
Debbi Fordgfisher@shire.com
debbi.ford@shire.com+1 781 482 9649
+1 617 949 9083

Dial in details for the live conference call for investors at 14:00 GMT / 10:00 EDT on November 1, 2016:
UK dial in:
US dial in:International Access Numbers:
Password/Conf ID:
Live Webcast:

0808 237 0030 or 020 3139 4830
1 866 928 7517 or 1 718 873 9077
Click here
42020034#
Click here

The quarterly earnings presentation will be available today at 13:00 GMT / 09:00 EDT on:- Shire.com Investors section- Shire's IR Briefcase in the iTunes Store

7

OVERVIEW OF THIRD QUARTER 2016 FINANCIAL RESULTS
1. Product Sales
For the three months ended Q3 2016, product sales increased 110% to $3,315 million (Q3 2015: $1,577 million),primarily due to the Baxalta transaction. Excluding legacy Baxalta, product sales increased 12% (up 13% on a Non
GAAP CER basis).
(in millions)

Product sales
HEMOPHILIAINHIBITOR THERAPIES
Hematology total

U.S. Sales
$

354.8
73.3
428.1

International
Sales
$

347.6
108.4
456.0

Total Sales$

Total SalesYear on year growth
Non GAAP
Reported
CER

702.4
181.7
884.1

N/A
N/A
N/A

N/A
N/A
N/A

CINRYZE
ELAPRASE
FIRAZYRREPLAGALVPRIVKALBITOR
Genetic Diseases total

151.6
38.0
129.1
—
39.8
11.1
369.6

13.8
108.7
17.2
118.9
47.9
—
306.5

165.4
146.7
146.3
118.9
87.7
11.1
676.1

-12%
+9%
+19%
+7%
+3%
N/A
+5%

-12%
+11%
+19%
+7%
+4%
N/A
+6%

VYVANSEADDERALL XROther Neuroscience
Neuroscience total

467.7
75.3
3.4
546.4

44.9
5.2
20.0
70.1

512.6
80.5
23.4
616.5

+20%
+3%
-21%
+15%

+20%
+3%
-18%
+16%

IMMUNOGLOBULIN THERAPIESBIO THERAPEUTICS
Immunology total

381.2
71.6
452.8

91.3
62.4
153.7

472.5
134.0
606.5

N/A
N/A
N/A

N/A
N/A
N/A

LIALDA/MEZAVANTPENTASAGATTEX/REVESTIVE
NATPARA
Other Internal Medicine
Internal Medicine total

188.4
85.4
49.5
23.3
35.0
381.6

20.2
—
8.6
—
52.3
81.1

208.6
85.4
58.1
23.3
87.3
462.7

+18%
-3%
+35%
+238%
+0%
+15%

+18%
-3%
+36%
+238%
+1%
+16%

Oncology total

44.9

10.5

55.4

N/A

N/A

Ophthalmology total

14.1

—

14.1

N/A

N/A

3,315.4+110%+111 %

Total product sales$

2,237.5$

1,077.9$

Hematology
The Hematology franchise was acquired with Baxalta in June 2016 and includes sales of recombinant and plasmaderived hemophilia products (primarily factor VIII and factor IX) and inhibitor therapies. Reported product sales in Q3
2016 were $884 million and represent 56 percentage points of Shire’s reported product sales growth. Underlying pro
forma Q3 2016 growth in Hematology was largely in line with market trends, but was impacted by the timing or large
orders.

8

Genetic Diseases
Genetic Diseases product sales in Q3 2016 increased 5% (up 6% on a Non GAAP CER basis) compared with Q3
2015, led by strong patient growth in FIRAZYR and across our LSD portfolio.
FIRAZYR sales increased 19% in Q3 2016 compared with Q3 2015 due to an increase in the number of patients ontherapy in both U.S. and international markets. The growth was held back by lower utilization per patient. CINRYZE
sales decreased by 12% in Q3 2016 compared with Q3 2015, as an increase in the number of patients on therapy
was more than offset by destocking and reduced utilization as a result of a U.S. supply constraint. Shire has taken
steps to increase CINRYZE production and expects to return to normalized supply by early 2017.
Neuroscience
Neuroscience product sales increased 15% (up 16% on a Non GAAP CER basis) in Q3 2016 compared with Q3 2015
with growth primarily driven by VYVANSE.
VYVANSE sales increased 20% due to year-over-year prescription growth in the U.S., the benefit of a price increasetaken since Q3 2015 and, to a lesser extent, increased stocking in Q3 2016 and growth in our international markets.
Immunology
The Immunology franchise was acquired with Baxalta in June 2016 and includes sales of antibody-replacement
immunoglobulin and bio therapeutics therapies. Reported product sales in Q3 2016 were $607 million and represent
38 percentage points of Shire’s reported product sales growth. Underlying pro forma Q3 2016 growth in Immunology
was largely in line with market trends, but was impacted by the timing or large orders, particularly our Bio Therapeutics
portfolio.
Internal Medicine
Internal Medicine product sales increased 15% (up 16% on a Non GAAP CER basis) in Q3 2016, with strong growthfrom LIALDA/MEZAVANT, GATTEX/REVESTIVE and NATPARA.
LIALDA/MEZAVANT sales increased 18% due to an increase in prescription demand, resulting in a market share of
40% at the end of Q3 2016 and the impact of a price increase taken since Q3 2015.
GATTEX/REVESTIVE and NATPARA continued to perform well with sales increasing 35% and 238%, respectively,
primarily due to an increase in the numbers of patients on therapy.
Oncology
The Oncology franchise was acquired with Baxalta in June 2016 and includes sales of ONCASPAR. Reported salesin Q3 2016 were $55 million and represent 4 percentage points of Shire’s reported product sales growth.
Ophthalmology
Product sales relate to XIIDRA, which was made available to patients on August 29, 2016. XIIDRA contributed $14
million of product sales in Q3 2016, primarily due to initial launch stocking.
Baxalta pro forma product sales growth
The following table presents Q3 2016 reported legacy Baxalta product sales compared with recast Q3 2015 pro forma
sales as previously reported by Baxalta following the separation from Baxter.
(in millions)

Reported product sales
HEMOPHILIAINHIBITOR THERAPIES
Hematology total

U.S. Sales
$

354.8
73.3
428.1

International
Sales
$

347.6
108.4
456.0

Total Sales$

Pro formaYear on year growth
Non GAAP
Reported
CER

702.4
181.7
884.1

-5%
-13%
-6%

-5%
-13%
-6%

IMMUNOGLOBULIN THERAPIESBIO THERAPEUTICS

381.2
71.6

91.3
62.4

472.5
134.0

+8%
-6%

+9%
-5%

Immunology total

452.8

153.7

606.5

+5%

+5%

Oncology total

44.9

10.5

55.4

+64%

+64%

1,546.0

-1%

-1%

Total

$

925.8

$

620.2

$

9

2. Royalties and other revenues(in millions)
Revenue
SENSIPAR Royalties
3TC and ZEFFIX Royalties
FOSRENOL Royalties
ADDERALL XR Royalties
Other Royalties and Revenues
Total Royalties and Other Revenues

38.7
16.2
13.7
4.7
63.4
136.7

$

$

Year on year growthReported
Non GAAP CER
+11%
+11%
+36%
+36%
+4%
-12%
-34%
-33%
+466%
+462%
+75%
+72%

Royalties and Other Revenues increased 75% in Q3 2016 compared with Q3 2015, primarily due to $39 million ofcontract manufacturing revenue acquired with Baxalta.
3. Financial Details
Cost of sales(in millions)
Cost of sales (US GAAP)
Cost of contract manufacturing revenue$

Cost of product sales
Amortization of inventory fair value step-up
Inventory write-down relating to the planned closureof a facility at the Los Angeles manufacturing site
Costs of employee retention awards following AbbVie
Inc.'s (AbbVie) terminated offer
Depreciation
Non GAAP cost of product sales$

Q3 2016
1,736.2(44.2)
1,692.0(803.8)% of product
sales
$
51%

Q3 2015
262.7
—
262.7
(6.7)

(11.6)——(54.5)
822.1

(1.0)
(9.6)
245.4

25% $

% of product
sales

17%

16%

US GAAP cost of product sales as a percentage of product sales increased in Q3 2016, primarily due to the impactof higher amortization of inventory fair value step-ups in 2016 following the acquisitions of Baxalta and Dyax and, toa lesser extent, the impact of lower margin product franchises acquired with Baxalta.
Non GAAP cost of product sales as a percentage of product sales increased to 25% in Q3 2016, primarily due to theimpact of lower margin product franchises acquired with Baxalta.
R&D(in millions)
R&D (US GAAP)
Costs relating to license arrangements
Costs of employee retention awards following
AbbVie's terminated offer
Depreciation
Non GAAP R&D$$

Q3 2016511.1(110.0)
—
(9.0)
392.1

% of product
sales
15% $

12% $

Q3 2015
241.2
—
(2.0)
(5.5)
233.7

% of product
sales
15%

15%

US GAAP R&D increased by $270 million, or 112%, primarily due to the inclusion of Baxalta and Dyax costs, and costs
related to licensing SHP647.
Non GAAP R&D increased by $158 million, or 68%, in Q3 2016 primarily due to the inclusion of Baxalta and Dyax
costs. Non GAAP R&D expense as a percentage of product sales decreased 3 percentage points.

10

SG&A
(in millions)
SG&A (US GAAP)(1)
Legal and litigation costs
Costs incurred in connection with AbbVie’s
terminated offer
Depreciation
Non GAAP SG&A$$

Q3 2016875.6
0.5—(29.6)
846.5% of product
sales
26% $

26% $

Q3 2015
442.3
(1.7)
(5.0)
(17.8)
417.8% of product
sales
28%

26%

US GAAP SG&A increased by $433 million, or 98%, primarily due to the inclusion of Baxalta related costs and XIIDRA
launch costs.
Non GAAP SG&A increased by $429 million, or 103%, compared with Q3 2015. Q3 2016 Non GAAP SG&A as apercentage of product sales remained consistent with Q3 2015 at 26%.
(1)

Reported SG&A for periods prior to Q3 2016 have been recast to exclude amortization of acquired intangible assets, which is now presented asa separate line item in the Unaudited Consolidated Statements of Operations.

Integration and acquisition costs
In Q3 2016, Shire recorded integration and acquisition costs of $285 million, primarily related to the Baxalta and Dyaxtransactions.
In Q3 2015, Shire recorded integration and acquisition costs of $90 million, which included costs related to the integrationof NPS and the proposed combination with Baxalta of $31 million. Additionally there was a net charge of $59 million
for the change in fair value of contingent consideration liabilities, primarily related to SHP625 (acquired with Lumena).
Amortization of acquired intangible assets
In Q3 2016, Shire recorded amortization of acquired intangible assets of $355 million (Q3 2015: $133 million). The
increase primarily related to amortization on the intangible assets acquired with the Baxalta and Dyax transactions.
Reorganization costs
In Q3 2016, Shire recorded reorganization costs of $101 million, primarily related to the planned closure of a facility
at the Los Angeles manufacturing site.
In Q3 2015, Shire recorded reorganization costs of $31 million, primarily related to the relocation of roles from
Pennsylvania to Massachusetts.

11Other expense, net(in millions)
Other expense, net (US GAAP)
Amortization of one-time upfront borrowing costs for
Baxalta and Dyax
Gain on sale of long term investments
Non GAAP Other expense, net$

Q3 2016(191.3)$47.4—(143.9)$Q3 2015(0.3)$—(10.4)(10.7)US GAAP Other expense, net increased $191 million, primarily due to higher interest expense and amortization of
one-time borrowing costs incurred on borrowings, including the write off of certain financing costs related to the bridge
facility for the Baxalta transaction. During Q3 2016, the bridge facility was fully repaid with the proceeds from the $12.1
billion public debt offering.
Non GAAP Other expense, net increased $133 million, primarily due to higher interest expense as noted above.
Taxation(in millions)
Income tax benefit (US GAAP)Tax effect of adjustments
Non GAAP Income tax charge$$

Q3 2016229.6(377.3)(147.7)

Effective
tax rate
38% $
13% $

Q3 2015
22.3(94.4)(72.1)

Effective
tax rate(5%)
10%

The effective tax rate on US GAAP income in Q3 2016 was 38% (Q3 2015: -5%) and on a Non GAAP basis was 13%(Q3 2015: 10%).
The effective tax rate in Q3 2016 on US GAAP income from continuing operations is higher primarily due to the
combined impact of the relative quantum of the profit before tax for the period by jurisdiction and the reversal ofdeferred tax liabilities from the Baxalta acquisition (including in higher tax territories), inventory and intangible asset
amortization, as well as acquisition and integration costs.
The Q3 2015 GAAP tax rate was negative primarily due to the release of certain valuation allowances and the effectof the finalization of various tax returns during the period.
The Q3 2016 Non GAAP tax rate is higher than the same period in 2015, primarily due to relatively higher discrete
benefits in Q3 2015 compared with Q3 2016 in relation to the release of certain valuation allowances and the effectof the finalization of various tax returns.
Discontinued operations
The loss from discontinued operations in Q3 2016 was $18 million, net of tax, primarily due to legal contingencies
related to the divested DERMAGRAFT business. The loss in Q3 2015 was $24 million, net of tax, primarily related toa change in estimate for onerous lease provisions.

12FINANCIAL INFORMATIONTABLE OF CONTENTS
Page
Unaudited US GAAP Consolidated Balance Sheets

14

Unaudited US GAAP Consolidated Statements of Operations

15

Unaudited US GAAP Consolidated Statements of Cash Flows17

Selected Notes to the Unaudited US GAAP Financial Statements(1) Earnings per share(2) Analysis of revenues

19
20

Non GAAP reconciliations

21

13

Unaudited US GAAP Consolidated Balance Sheets(in millions, except par value of shares)

September 30, 2016
ASSETS
Current assets:
Cash and cash equivalents
Restricted cash
Accounts receivable, net
Inventories
Prepaid expenses and other current assets
Total current assets$

Non-current assets:
Investments
Property, plant and equipment (PP&E), net
Goodwill
Other intangible assets, net
Deferred tax asset
Other non-current assets
Total assets
LIABILITIES AND EQUITYCurrent liabilities:
Accounts payable and accrued expenses
Short term borrowings
Other current liabilities
Total current liabilities

728.6
20.1
2,633.4
4,857.1
665.3
8,904.5

December 31, 2015

$

191.8
6,527.7
14,850.6
38,871.5
109.0
296.2

135.5
86.0
1,201.2
635.4
197.4
2,255.5
50.8
828.1
4,147.8
9,173.3
121.0
33.3

$

69,751.3$

16,609.8$

4,021.7
2,737.1
352.1
7,110.9$

2,050.6
1,511.5
144.0
3,706.1

Non-current liabilities:
Long term borrowings
Deferred tax liability
Other non-current liabilities

20,988.9
9,326.5
2,539.3

69.9
2,205.9
798.8

Total liabilities

39,965.6

6,780.7

Equity:Common stock of 5p par value; 1,000 shares authorized; and910.9 shares issued and outstanding (2015: 1,000 sharesauthorized; and 601.1 shares issued and outstanding)
Additional paid-in capital
Treasury stock: 9.1 shares (2015: 9.7 shares)
Accumulated other comprehensive loss
Retained earnings
Total equity

81.3
24,631.3(302.2)(134.2)5,509.5
29,785.7

58.9
4,486.3(320.6)(183.8)5,788.3
9,829.1

Total liabilities and equity$

69,751.3$

16,609.8

14

Unaudited US GAAP Consolidated Statements of Operations(in millions)
3 months ended
September 30,
2016
2015
Revenues:
Product sales
Royalties & other revenues
Total revenues

9 months ended
September 30,
2016
2015

$ 3,315.4
136.7
3,452.1$ 1,576.8
78.2
1,655.0$ 7,264.8
325.7
7,590.5$ 4,476.2
224.8
4,701.0

Costs and expenses:
Cost of sales
Research and development
Selling, general and administrative(1)Amortization of acquired intangible assets
Integration and acquisition costs
Reorganization costs
Gain on sale of product rights
Total operating expenses

1,736.2
511.1
875.6
354.9
284.5
101.4
(5.7)
3,858.0

262.7
241.2
442.3
132.7
89.9
31.1
(0.7)
1,199.2

2,762.9
1,023.0
2,025.8
702.5
738.6
115.7
(12.2)
7,356.3

718.5
1,210.8
1,356.6
352.3(46.8)
59.6(13.0)
3,638.0

Operating (loss)/income from continuing operations(405.9)

455.8

234.2

1,063.0

Interest income
Interest expense
Other (expense)/income, net
Total other expense, net

9.3(186.9)(13.7)(191.3)0.8(10.7)
9.6
(0.3)

11.9
(318.8)(16.2)(323.1)

3.4(31.6)
11.9(16.3)(Loss)/income from continuing operations before income
taxes and equity in losses of equity method investees
Income taxes
Equity in losses of equity method investees, net of taxes(Loss)/income from continuing operations, net of taxes(597.2)229.6(0.9)(368.5)

455.5
22.3
(0.7)
477.1

(88.9)
218.4
(1.9)
127.6

1,046.7
9.0(1.6)
1,054.1

Loss from discontinued operations, net of taxes(18.3)(24.3)(257.5)(31.3)(386.8) $452.8

Net (loss)/income$$(129.9) $ 1,022.8(1)

Reported SG&A for periods prior to September 30, 2016 have been recast to exclude amortization of acquired intangible assets, which is
now presented as a separate line item.

15

Unaudited US GAAP Consolidated Statements of Operations (continued)(in millions, except per share amounts)
3 months ended
September 30,
2016
2015
(Loss)/earnings per Ordinary Share – basic(Loss)/earnings from continuing operations
Loss from discontinued operations(Loss)/earnings per Ordinary Share – basic(Loss)/earnings per ADS – basic(Loss)/earnings per Ordinary Share – diluted(Loss)/earnings from continuing operations
Loss from discontinued operations(Loss)/earnings per Ordinary Share – diluted(Loss)/earnings per ADS – diluted
Weighted average number of shares:
Basic
Diluted

$
$
$

$
$
$

9 months ended
September 30,
2016
2015

(0.41) $(0.02)(0.43) $(1.29) $0.81 $(0.04)
0.77 $
2.30 $

0.18 $(0.36)(0.18) $(0.54) $1.79(0.06)
1.73
5.20(0.41) $(0.02)(0.43) $(1.29) $0.80 $(0.04)
0.76 $
2.29 $

0.18 $(0.36)(0.18) $(0.54) $1.78(0.06)
1.72
5.17

900.2
900.2

590.9
593.4

725.5
725.5

590.2
593.2

16

Unaudited US GAAP Consolidated Statements of Cash Flows(in millions)
3 months ended
September 30,
2016
2015
CASH FLOWS FROM OPERATING ACTIVITIES:Net (loss)/income$
Adjustments to reconcile net (loss)/income to net cash
provided by operating activities:
Depreciation and amortization
Share based compensation
Amortization of deferred financing fees
Amortization of inventory fair value step-up
Change in deferred taxes
Change in fair value of contingent consideration
Impairment of intangible assets
Impairment of PP&E
Other, net
Changes in operating assets and liabilities:
Increase in accounts receivable
Increase in sales deduction accrual(Increase)/decrease in inventory(Increase)/decrease in prepayments and other assets(Decrease)/increase in accounts payable and other liabilities
Net cash provided by operating activities
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of PP&E and non-current investments
Purchases of businesses, net of cash acquired
Proceeds from short-term investments
Proceeds from disposal of non-current investments
Movements in restricted cash
Proceeds received on sale of product rights
Other, net
Net cash used in investing activities

9 months ended
September 30,
2016
2015

(386.8) $

452.8

448.0
74.8
71.6
803.8
(217.7)
10.2
—
86.5
55.6

165.6
26.5
3.6
6.7
(98.9)
59.2——(18.5)

877.8
269.6
121.7
1,097.3(546.9)(34.8)
8.9
89.2
35.3

457.4
70.8
8.0
23.0
(178.3)(196.5)523.3—(23.2)(230.2)41.8(111.6)(92.9)(27.5)
525.6(203.2)
62.7
15.7
(7.2)
96.3
561.3

(411.2)108.2(228.0)(66.4)
315.2
1,506.0(288.1)
100.0(21.7)
21.2
56.5
1,575.2(223.4)
—
—
0.6
1.1
2.2
(7.0)
(226.5)(22.6)(304.2)—
14.1(28.5)
5.7
3.6(331.9)(402.5)(17,476.2)
—
0.6
68.3
7.8
(9.3)
(17,811.3)(67.3)(5,553.4)
67.0
18.5(48.0)
14.5
2.7(5,566.0)$(129.9) $ 1,022.8

17

Unaudited US GAAP Consolidated Statements of Cash Flows (continued)(in millions)

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from revolving line of credit, long term and shortterm borrowings
Repayment of revolving line of credit, long term and short term
borrowings
Payment of dividend
Debt issuance costs
Proceeds from exercise of options
Other, net
Net cash (used in)/provided by financing activities

3 months ended
September 30,
2016
2015

9 months ended
September 30,
2016
2015

12,847.3

725.2

31,742.3

3,650.8(13,132.6)—(58.7)
98.7(18.3)(263.6)(955.2)—0.4—(18.0)(247.6)(14,632.9)(130.2)(171.0)98.9(6.5)
16,900.6(2,486.1)(110.2)(3.3)—
3.7
1,054.9

(0.3)

(0.9)

(2.2)

(1.6)

35.2
693.4
728.6

(19.1)
64.0
44.9 $

593.1
135.5
728.6

(2,937.5)
2,982.4
44.9$

Effect of foreign exchange rate changes on cash and cash
equivalents
Net increase/(decrease) in cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period

$

$

18

Selected Notes to the Unaudited US GAAP Financial Statements(1) Earnings Per Share (EPS)(in millions)(Loss)/income from continuing operations
Loss from discontinued operations
Numerator for EPS
Weighted average number of shares:
Basic
Effect of dilutive shares:
Share based awards to employees
Diluted

3 months ended
9 months ended
September 30,
September 30,
2016
2015
2016
2015
$ (368.5) $477.1 $
127.6 $ 1,054.1(18.3)(24.3)(257.5)(31.3)$ (386.8) $452.8 $ (129.9) $ 1,022.8
900.2

590.9

725.5

590.2

—
900.2

2.5
593.4

—
725.5

3.0
593.2

The share equivalents not included in the calculation of the diluted weighted average number of shares are shown
below:
Share based awards to employees

14.6

3.9

9.7

3.3

19

Selected Notes to the Unaudited US GAAP Financial Statements(2) Analysis of revenues(in millions)
3 months ended
September 30,
2016
2015

9 months ended
September 30,
2016
2015

Product sales:
HEMOPHILIAINHIBITOR THERAPIES
Hematology total

$

702.4
181.7
884.1

$

—
—
—

$

978.0
255.7
1,233.7$———

CINRYZE
ELAPRASE
FIRAZYRREPLAGALVPRIVKALBITOR
Genetic Diseases total

165.4
146.7
146.3
118.9
87.7
11.1
676.1

187.5
134.0
123.2
111.1
85.1
—
640.9

502.6
424.3
411.3
340.5
259.3
39.2
1,977.2

474.4
405.5
319.8
325.5
256.2
—
1,781.4

VYVANSEADDERALL XROther Neuroscience
Neuroscience total

512.6
80.5
23.4
616.5

427.3
78.0
29.5
534.8

1,539.5
281.1
81.2
1,901.8

1,268.9259.7
81.9
1,610.5

IMMUNOGLOBULIN THERAPIESBIO THERAPEUTICS
Immunology total

472.5
134.0
606.5

—
—
—

610.7
185.3
796.0

—
—
—

LIALDA/MEZAVANTPENTASAGATTEX/REVESTIVE
NATPARA
Other Internal Medicine
Internal Medicine total

208.6
85.4
58.1
23.3
87.3
462.7

176.6
87.7
43.0
6.9
86.9
401.1

570.3
222.3
154.3
58.8
260.6
1,266.3

483.0
232.7
95.2
12.8
260.6
1,084.3

Oncology total

55.4

—

75.7

—

Ophthalmology total

14.1

—

14.1

—

Total product sales

3,315.4

1,576.8

7,264.8

4,476.2

38.7
16.2
13.7
4.7
63.4
136.7

34.8
11.9
13.2
7.1
11.2
78.2

112.2
43.3
34.3
15.7
120.2
325.7

80.0
29.9
32.4
22.2
60.3
224.8

$ 3,452.1$ 1,655.0$ 7,590.5$ 4,701.0

Royalties and Other Revenues:
SENSIPAR Royalties
3TC and ZEFFIX Royalties
FOSRENOL Royalties
ADDERALL XR Royalties
Other Royalties and Revenues
Total Royalties and Other Revenues
Total Revenues

20Non GAAP reconciliations(in millions)
Reconciliation of US GAAP net (loss)/income to Non GAAP EBITDA:

US GAAP Net (loss)/income
Add back/(deduct):
Loss from discontinued operations, net of tax
Equity in losses of equity method investees, net of taxes
Income taxes
Other expense, net
US GAAP Operating (loss)/income from continuing operations
Add back/(deduct) Non GAAP adjustments:
Acquisition and integration activities
Amortization of acquired intangible assets
Divestments and reorganizations
Depreciation
Legal and litigation costs
Impairment of intangible assets
Other
Non GAAP EBITDA
Depreciation
Non GAAP Operating income
Net (loss)/income margin(1)Non GAAP EBITDA margin(2)3 months ended
September 30,
2016
2015
$ (386.8)$ 452.8

9 months ended
September 30,
2016
2015
$ (129.9)$ 1,022.8

18.3
0.9(229.6)191.3(405.9)24.3
0.7(22.3)
0.3
455.8

257.5
1.9
(218.4)
323.1
234.2

31.3
1.6
(9.0)
16.3
1,063.0

1,198.3
354.9
107.3
93.1
(0.5)
—
—
1,347.2(93.1)

96.6
132.7
30.4
32.9
1.7
—
8.0
758.1
(32.9)
725.2

1,945.9
702.5
115.1
175.3
16.1
8.9
—
3,198.0(175.3)(23.8)
352.3
46.6
105.1
4.4
523.3
56.0
2,126.9(105.1)$ 2,021.8$1,254.1
(11%)
38%

$

27%
43%

$3,022.7
(2%)
40%

22%
43%

(1)

Net income as a percentage of total revenues.

(2)

Non GAAP EBITDA as a percentage of product sales, excluding royalties and other revenues, and cost of contract manufacturing revenues.

Reconciliation of US GAAP product sales to Non GAAP Gross Margin:

US GAAP Product Sales(Deduct)/add back:
Cost of sales (US GAAP)
Cost of contract manufacturing revenue
Amortization of inventory fair value step-up
Inventory write-down relating to the planned closure of a
facility at the Los Angeles manufacturing site
Costs of employee retention awards following AbbVie's
terminated offer
Depreciation
Non GAAP Gross Margin
Non GAAP Gross Margin % (1)(1)

3 months ended
September 30,
2016
2015
$ 3,315.4$ 1,576.8

9 months ended
September 30,
2016
2015
$ 7,264.8$ 4,476.2(1,736.2)
44.2
803.8

(262.7)—6.7(2,762.9)
61.4
1,097.3(718.5)
—
23.0

11.6

—

11.6

—

—
1.0
—
6.5
54.5
9.6
85.2
34.4
$ 2,493.3$ 1,331.4$ 5,757.4$ 3,821.6
75.2%
84.4%
79.3%
85.4%

Non GAAP Gross Margin as a percentage of product sales.

21Non GAAP reconciliations(in millions, except per ADS amounts)
Reconciliation of US GAAP diluted earnings per ADS to Non GAAP diluted earnings per ADS:US GAAP diluted (loss)/earnings per ADS
Amortization and asset impairments
Acquisition and integration costs
Divestments, reorganizations and discontinued operations
Legal and litigation costs
Other Non GAAP adjustments
Tax effect of adjustments above
Non GAAP diluted earnings per ADS

3 months ended
9 months ended
September 30,
September 30,
2016
2015
2016
2015
(1.29) $2.29 $(0.54) $
5.17
$
1.17
0.67
2.92
4.43
4.11
0.49
8.36
(0.12)
0.43
0.30
1.97
0.41
—
0.01
0.07
0.02
—
0.04
—
0.28
(1.25)(0.56)(3.07)(1.48)
3.17 $
3.24 $
9.71 $
8.71$

Reconciliation of US GAAP net cash provided by operating activities to Non GAAP cash generation:

Net cash provided by operating activities
Tax and interest payments, net
Up-front payments for in-licensed and acquired products
Non GAAP cash generation

3 months ended
September 30,
2016
2015
525.6 $
561.3
$
214.1
26.4
90.0
—
829.7 $
587.7$

9 months ended
September 30,
2016
2015
$ 1,506.0 $ 1,575.2
579.2
33.6
90.0
—
$ 2,175.2 $ 1,608.8

Reconciliation of US GAAP net cash provided by operating activities to Non GAAP free cash flow:

Net cash provided by operating activities
Capital expenditure
Up-front payments for in-licensed and acquired products
Non GAAP free cash flow

3 months ended
9 months ended
September 30,
September 30,
2016
2015
2016
2015
525.6 $
561.3 $ 1,506.0 $ 1,575.2$(220.8)(22.3)(399.6)(62.1)
90.0
—
90.0
—
394.8 $
539.0 $ 1,196.4 $ 1,513.1$

Non GAAP net debt comprises:

Cash and cash equivalents
Long term borrowings
Short term borrowings
Other debt
Non GAAP net debt

September 30, 2016
728.6 $$
(20,988.9)(2,737.1)(348.6)(23,346.0) $$December 31, 2015
135.5
(69.9)(1,511.5)(13.4)(1,459.3)

22

Non GAAP reconciliations(in millions, except per ADS amounts)
Reconciliation of full year 2016 US GAAP diluted earnings per ADS Outlook to Non GAAP diluted earnings per ADS
Outlook:

US GAAP diluted earnings per ADS
Amortization and asset impairments
Acquisition and integration costs
Divestments, reorganizations and discontinued operations
Legal and litigation costs
Tax effect of adjustments above
Non GAAP diluted earnings per ADS$$

Full Year 2016 Outlook
MinMax(1.10)—(0.70)
$
4.13
11.74
1.96
0.06
(4.09)
12.70—$ 13.1023

NOTES TO EDITORS
Stephen Williams, Deputy Company Secretary (responsible for arranging the release of this announcement).
Inside Information
This announcement contains inside information.
About Shire
Shire is the leading global biotechnology company focused on serving people with rare diseases and other highly
specialized conditions. We strive to develop best-in-class products, many of which are available in more than 100
countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics,
Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; and a
growing franchise in Oncology.
Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies forthe hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and wholack effective therapies to live their lives to the fullest.
www.shire.com

24THE “SAFE HARBOR” STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT
OF 1995
Statements included herein that are not historical facts, including without limitation statements concerning future
strategy, plans, objectives, expectations and intentions, the anticipated timing of clinical trials and approvals for, andthe commercial potential of, inline or pipeline products are forward-looking statements. Such forward-looking statements
involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties
materialize, Shire’s results could be materially adversely affected. The risks and uncertainties include, but are notlimited to, the following:• Shire’s products may not be a commercial success;• increased pricing pressures and limits on patient access as a result of governmental regulations and market
developments may affect Shire’s future revenues, financial condition and results of operations;• Shire conducts its own manufacturing operations for certain of its products and is reliant on third party contract
manufacturers to manufacture other products and to provide goods and services. Some of Shire’s products or
ingredients are only available from a single approved source for manufacture. Any disruption to the supply chain for
any of Shire’s products may result in Shire being unable to continue marketing or developing a product or may resultin Shire being unable to do so on a commercially viable basis for some period of time;• the manufacture of Shire’s products is subject to extensive oversight by various regulatory agencies. Regulatory
approvals or interventions associated with changes to manufacturing sites, ingredients or manufacturing processes
could lead to significant delays, an increase in operating costs, lost product sales, an interruption of research activitiesor the delay of new product launches;• certain of Shire’s therapies involve lengthy and complex processes, which may prevent Shire from timely responding
to market forces and effectively managing its production capacity;• Shire has a portfolio of products in various stages of research and development. The successful development ofthese products is highly uncertain and requires significant expenditures and time, and there is no guarantee thatthese products will receive regulatory approval;• the actions of certain customers could affect Shire’s ability to sell or market products profitably. Fluctuations in buying
or distribution patterns by such customers can adversely affect Shire’s revenues, financial conditions or results ofoperations;• Shire’s products and product candidates face substantial competition in the product markets in which it operates,
including competition from generics;• adverse outcomes in legal matters, tax audits and other disputes, including Shire’s ability to enforce and defend
patents and other intellectual property rights required for its business, could have a material adverse effect on the
combined company’s revenues, financial condition or results of operations;• inability to successfully compete for highly qualified personnel from other companies and organizations;• failure to achieve the strategic objectives with respect to Shire’s acquisition of NPS, Dyax or Baxalta may adversely
affect Shire’s financial condition and results of operations;• Shire’s growth strategy depends in part upon its ability to expand its product portfolio through external collaborations,which, if unsuccessful, may adversely affect the development and sale of its products;• a slowdown of global economic growth, or economic instability of countries in which Shire does business, as well
as changes in foreign currency exchange rates and interest rates, that adversely impact the availability and cost of
credit and customer purchasing and payment patterns, including the collectability of customer accounts receivable;• failure of a marketed product to work effectively or if such a product is the cause of adverse side effects could resultin damage to Shire’s reputation, the withdrawal of the product and legal action against Shire;• investigations or enforcement action by regulatory authorities or law enforcement agencies relating to Shire’s activities
in the highly regulated markets in which it operates may result in significant legal costs and the payment of substantial
compensation or fines;• Shire is dependent on information technology and its systems and infrastructure face certain risks, including fromservice disruptions, the loss of sensitive or confidential information, cyber-attacks and other security breaches ordata leakages that could have a material adverse effect on Shire’s revenues, financial condition or results ofoperations;• Shire incurred substantial additional indebtedness to finance the Baxalta acquisition, which may decrease its
business flexibility and increase borrowing costs;• difficulties in integrating Dyax or Baxalta into Shire may lead to the combined company not being able to realize theexpected operating efficiencies, cost savings, revenue enhancements, synergies or other benefits at the time
anticipated or at all; and25

other risks and uncertainties detailed from time to time in Shire’s filings with the Securities and Exchange Commission,
including those risks outlined in “ITEM 1A: Risk Factors” in Shire’s Quarterly Report on Form 10-Q for the quarter
ended June 30, 2016.
All forward-looking statements attributable to us or any person acting on our behalf are expressly qualified in their
entirety by this cautionary statement. Readers are cautioned not to place undue reliance on these forward-looking
statements that speak only as of the date hereof. Except to the extent otherwise required by applicable law, we do notundertake any obligation to update or revise forward-looking statements, whether as a result of new information, future
events or otherwise.

26

NON GAAP MEASURESThis press release contains financial measures not prepared in accordance with US GAAP. These measures arereferred to as “Non GAAP” measures and include: Non GAAP operating income; Non GAAP net income; Non GAAP
diluted earnings per ADS; effective tax rate on Non GAAP income before income taxes and (losses/earnings) of equity
method investees (effective tax rate on Non GAAP income); Non GAAP CER; Non GAAP cost of product sales; Non
GAAP gross margin; Non GAAP R&D; Non GAAP SG&A; Non GAAP other expense; Non GAAP cash generation; Non
GAAP free cash flow, Non GAAP net debt, Non GAAP EBITDA and Non GAAP EBITDA margin (excluding royalties
and other revenues and cost of sales related to contract manufacturing revenues).
The Non GAAP measures exclude the impact of certain specified items that are highly variable, difficult to predict, andof a size that may substantially impact Shire’s operations. Upfront and milestone payments related to in-licensing andacquired products that have been expensed as R&D are also excluded as specified items as they are generally
uncertain and often result in a different payment and expense recognition pattern than ongoing internal R&D activities.
Intangible asset amortization has been excluded from certain measures to facilitate an evaluation of current and past
operating performance, particularly in terms of cash returns, and is similar to how management internally assesses
performance. The Non GAAP financial measures are presented in this press release as Shire’s management believes
that they will provide investors with an additional analysis of Shire’s results of operations, particularly in evaluating
performance from one period to another.
Shire’s management uses Non GAAP financial measures to make operating decisions as they facilitate additional
internal comparisons of Shire’s performance to historical results and to competitor’s results, and provides them toinvestors as a supplement to Shire’s reported results to provide additional insight into Shire’s operating performance.
Shire’s Remuneration Committee uses certain key Non GAAP measures when assessing the performance andcompensation of employees, including Shire’s executive directors.
The Non GAAP financial measures used by Shire may be calculated different from, and therefore may not be comparable
to, similarly titled measures used by other companies - refer to the section “Non GAAP Financial Measure Descriptions”
below for additional information. In addition, these Non GAAP financial measures should not be considered in isolation
as a substitute for, or as superior to, financial measures calculated in accordance with US GAAP, and Shire’s financial
results calculated in accordance with US GAAP and reconciliations to those financial statements should be carefully
evaluated.
Non GAAP Financial Measure Descriptions
Where applicable the following items, including their tax effect, have been excluded when calculating Non GAAP
earnings and from our outlook:••

Amortization and asset impairments:
Intangible asset amortization and impairment charges; andOther than temporary impairment of investments.

Acquisitions and integration activities:
Up-front payments and milestones in respect of in-licensed and acquired products;
Costs associated with acquisitions, including transaction costs, fair value adjustments on contingent consideration
and acquired inventory;• Costs associated with the integration of companies; and• Noncontrolling interests in consolidated variable interest entities.

•
•

•
•
•
•

•

Divestments, reorganizations and discontinued operations:
Gains and losses on the sale of non-core assets;
Costs associated with restructuring and reorganization activities;
Termination costs; andIncome/(losses) from discontinued operations.
Legal and litigation costs:
Net legal costs related to the settlement of litigation, government investigations and other disputes (excluding internal
legal team costs).

27

Additionally, in any given period Shire may have significant, unusual or non-recurring gains or losses which it may
exclude from its Non GAAP earnings for that period. When applicable, these items would be fully disclosed andincorporated into the required reconciliations from US GAAP to Non GAAP measures.
Depreciation, which is included in Cost of product sales, R&D and SG&A costs in our US GAAP results, has been
separately disclosed for presentational purposes.
Cash generation represents net cash provided by operating activities, excluding up-front and milestone payments forin-licensed and acquired products, tax and interest payments.
Free cash flow represents net cash provided by operating activities, excluding up-front and milestone payments forin-licensed and acquired products, but including capital expenditure in the ordinary course of business.
Non GAAP net debt represents cash and cash equivalents less short and long term borrowings and other debt.
A reconciliation of Non GAAP financial measures to the most directly comparable measure under US GAAP is presented
on pages 21 to 23.
Non GAAP CER growth is computed by restating 2016 results using average 2015 foreign exchange rates for the
relevant period.
Average exchange rates used by Shire for Q3 2016 were $1.32:£1.00 and $1.11:€1.00 (2015: $1.56:£1.00 and $1.11:€1.00). Average exchange rates used by Shire for the nine months to September 30, 2016 were $1.40:£1.00 and$1.11:€1.00 (2015: $1.54:£1.00 and $1.12:€1.00).

TRADEMARKSWe own or have rights to trademarks, service marks or trade names that we use in connection with the operation of
our business. In addition, our names, logos and website names and addresses are owned by us or licensed by us.
We also own or have the rights to copyrights that protect the content of our solutions. Solely for convenience, thetrademarks, service marks, trade names and copyrights referred to in this press release are listed without the ©, ®
and ™ symbols, but we will assert, to the fullest extent under applicable law, our rights or the rights of the applicable
licensors to these trademarks, service marks, trade names and copyrights. In addition, this press release may include
trademarks, service marks or trade names of other companies. Our use or display of other parties’ trademarks, service
marks, trade names or products is not intended to, and does not imply a relationship with, or endorsement or sponsorshipof us by, the trademark, service mark or trade name.

28